Collaborative discussions” with the FDA encouraged Praxis to submit early next year an approval filing for its epilepsy drug. Elsewhere, Rezolute shares plunged and Centessa announced a new CEO.

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor ...

Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong ...

The EMBOLD study of relutrigine (also known as PRAX-562) was testing the oral drug in patients with SCN2A and SCN8A ...

Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug ...

BTIG raised the firm’s price target on Praxis Precision (PRAX) to $499 from $424 and keeps a Buy rating on the shares. The firm also names the ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock dropped 4% on Thursday following the release of a critical short report from Culper Research questioning the company’s Phase 3 trial ...

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

The Praxis® tests are a series of exams required by the Kentucky Education Professional Standards Board for individuals entering an educator preparation program and seeking certification to teach.

Praxis Precision Medicines surged after positive Essential3 data for ulixacaltamide in essential tremor, but tolerability issues limit enthusiasm. Ulixacaltamide demonstrated functional benefit, but ...